Specifically, BLC, Eotaxin-2, M-CSF, and TIMP-1 could potentially aid in the diagnosis and prediction of fibrosis progress of MPN subtypes as non-invasive biomarkers. The gene discussed is CCL24; the disease is myeloproliferative neoplasm.